Brooke McCormick

The phase 3 IRAKLIA trial assesses subcutaneous isatuximab via on-body injector vs intravenous (IV) administration, in combination with pomalidomide and dexamethasone, in relapsed/refractory multiple myeloma (RRMM).

Patients with relapsed/refractory (R/R) multiple myeloma and lower socioeconomic status reported significantly worse quality of life and a higher burden of symptoms, according to Francesco Sparano, MSc, of the GIMEMA Foundation.

Early results from the phase 1 SANRECO trial suggest that divesiran is safe and well tolerated, and may reduce the need for phlebotomy in patients with polycythemia vera by increasing hepcidin levels and improving iron regulation, according to lead investigator Marina Kremyanskaya, MD, PhD.

Sundar Jagannath, MBBS, highlights long-term follow-up data from the phase 1b/2 CARTITUDE-1 trial, showing durable responses and potential cures with ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma.

An artificial intelligence (AI)-driven machine learning model was refined and validated internationally to accurately classify acute leukemia subtypes from routine laboratory data, according to Merlin Engelke, MS, offering a potential tool for improving diagnosis worldwide.

In this clip, Adela Perolla, MD, PhD, discusses the urgent need to address and destigmatize burnout in hematology, especially among early-career professionals, by promoting self-awareness, work-life balance, and peer support.

Burnout is rising sharply in hematology due to emotional strain, long hours, and high patient demands, according to Adela Perolla, MD, PhD, impacting both physician well-being and patient care.

Ola Landgren, MD, PhD, shares ADVANCE trial results, which show that adding daratumumab to carfilzomib-lenalidomide-dexamethasone (DKRd) improves outcomes in newly diagnosed multiple myeloma.

Ola Landgren, MD, PhD, lead investigator of the ADVANCE clinical trial, outlines the study’s goal of advancing modern, minimal residual disease–guided treatment approaches.

In the final part of an interview with Brian Slomovitz, MD, he highlights that the phase 3 ROSELLA trial demonstrates a safe, effective treatment for platinum-resistant ovarian cancer that does not require biomarker testing.

Julia Lucaci, PharmD, MS, of Becton, Dickinson and Company, discusses the benefits of blister packaging for chronic medications, advocating for payer incentives to boost medication adherence and improve health outcomes.

With the FDA approval of retifanlimab (Zynyz; Incyte) as the first and only first-line treatment for advanced anal cancer, researchers are now focusing on resistance mechanisms and future therapies, according to Sheela Rao, MBBS, MD, FRCP, of The Royal Marsden Hospital.

In the final part of her interview, Margrit Wiesendanger, MD, PhD, discusses the need to improve lupus care by addressing social determinants of health and expanding access to treatment.

Ahead of the 30th European Hematology Association (EHA) Congress in Milan, Ola Landgren, MD, PhD, shares what he is most looking forward to and reflects on key advancements and ongoing challenges in hematology.

Inhaled corticosteroid (ICS) use was common among patients with bronchiectasis and was associated with reduced exacerbations and hospitalizations in those with elevated blood eosinophil counts.

In May, the FDA granted significant drug approvals across various therapeutic areas, marking notable progress in expanding treatment options for patients.

Brian Slomovitz, MD, of Mount Sinai Medical Center, compares relacorilant plus nab-paclitaxel with existing treatments for platinum-resistant ovarian cancer and highlights the ROSELLA trial’s global scope.

Ponatinib shows promising results in achieving MRD negativity and improved event-free survival in Ph+ ALL patients compared to imatinib, according to ASCO findings.

Men’s Health Month 2025 encourages men to adopt preventive care and healthy lifestyle habits to improve overall health outcomes.

Relacorilant combined with nab-paclitaxel (Abraxane) significantly improved progression-free and overall survival in patients with platinum-resistant ovarian cancer in the phase 3 ROSELLA trial, according to Brian Slomovitz, MD, one of the investigators.

US workers facing high economic hardship, especially those in lower-wage occupations, were significantly more likely to report fair or poor health, underscoring persistent disparities in worker well-being.

Oncology biosimilars significantly reduce financial toxicity in cancer care, as highlighted in 2 abstracts presented at the 2025 American Society of Clinical Oncology Annual Meeting.

Margrit Wiesendanger, MD, PhD, highlights how social determinants of health and equitable treatment access are critical to improving lupus outcomes, particularly in minority populations.

New findings reveal that relacorilant enhances survival rates in platinum-resistant ovarian cancer when combined with nab-paclitaxel, outperforming standard treatment.

CK Wang, MD, explains that Black women face higher rates of late-stage breast and ovarian cancer diagnoses, demonstrating the need for better screening guidelines and more representative data.

Concurrent hypertension and type 2 diabetes significantly increase mortality risk, emphasizing the need for targeted health interventions to improve outcomes.

Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.

Abstracts published ahead of the 2025 American Society of Clinical Oncology Annual Meeting found persistent ovarian cancer survival disparities among racial and ethnic subgroups, particularly within disaggregated Asian American, Native Hawaiian, and Pacific Islander populations.

Gerard Criner, MD, FACP, FACCP, MATINEE investigator, highlights trial results that showed reduced exacerbations and delayed disease progression in patients with eosinophilic chronic obstructive pulmonary disease (COPD).

Evernorth has capped antiobesity drug monthly co-pays at $200 in a move to improve access and affordability amid new drug pricing initiatives.